New drug tested for rare Muscle-Wasting disease
NCT ID NCT06411912
Summary
This study tested whether an investigational drug called NIDO-361 is safe and effective for adults with spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease. It involved 54 men with SBMA who were randomly assigned to receive either the drug or a placebo for nearly a year. Researchers measured changes in muscle volume, walking ability, and other physical functions to see if the drug could help control the progression of this genetic muscle-wasting condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL AND BULBAR MUSCULAR ATROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedale Università di Padova
Padua, Italy
-
IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
-
Kyungpook National University Chilgok Hospital
Daegu, South Korea
-
Rigshospitalet, Klinik for Nerve- og Muskelsygdomme & Copenhagen Neuromuscular Center
Copenhagen, Denmark
-
University of College London Hospital (UCLH)
London, United Kingdom
Conditions
Explore the condition pages connected to this study.